Critical Contrast: Rexahn Pharmaceuticals (NASDAQ:REXN) versus Myovant Sciences (NASDAQ:MYOV)
Rexahn Pharmaceuticals (NASDAQ:REXN) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Earnings & Valuation
This table compares Rexahn Pharmaceuticals and Myovant Sciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rexahn Pharmaceuticals||N/A||N/A||-$8.64 million||N/A||N/A|
|Myovant Sciences||N/A||N/A||-$273.55 million||($4.09)||-2.99|
Risk and Volatility
Rexahn Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500.
Insider & Institutional Ownership
6.2% of Rexahn Pharmaceuticals shares are held by institutional investors. Comparatively, 36.9% of Myovant Sciences shares are held by institutional investors. 1.1% of Rexahn Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Myovant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings and price targets for Rexahn Pharmaceuticals and Myovant Sciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Myovant Sciences has a consensus target price of $23.75, suggesting a potential upside of 94.35%. Given Myovant Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Myovant Sciences is more favorable than Rexahn Pharmaceuticals.
This table compares Rexahn Pharmaceuticals and Myovant Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Myovant Sciences beats Rexahn Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.